Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues
- 24 April 2006
- journal article
- research article
- Published by Wiley in Tissue Antigens
- Vol. 67 (4) , 307-317
- https://doi.org/10.1111/j.1399-0039.2006.00584.x
Abstract
OX40, a membrane‐bound molecule of the tumor‐necrosis‐factor‐receptor superfamily, is a critical costimulatory receptor during the immune response. Here, we newly generated two specific mouse antihuman OX40 monoclonal antibodies (mAbs) (2G2 and 1F7), whose specificities are quite different from the available OX40 mAb (ACT35) by competition assay. It was also found that both mAbs could enhance the proliferation, activation and differentiation of T lymphocytes primed by anti‐CD3 mAb. These results evidenced that both were functional antihuman OX40 mAbs. Furthermore, stained by 2G2 and 1F7, FCM and immunohistochemistry detected the constitutive expression of OX40 on tumor cell lines from epithelium, breast cancer and glioma tissues. Meanwhile, the non‐tumor tissues (thyroid gland, stomach gland) were also found OX40 expression. These results suggested that OX40 is not only expressed in activated T cells, but also in some tumors as well as normal gland tissues. Such expression pattern indicated that OX40 may be a valuable surface antigen in unveiling its expression and function outside the immune system. Briefly, these novel antibodies may contribute to the evaluation of the mechanism of tumor metastasis and eventually shed light on further study of tumor immunotherapy and autoimmune diseases.Keywords
This publication has 31 references indexed in Scilit:
- Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40Cancer Research, 2005
- Characterization and application of two novel monoclonal antibodies against 2IgB7‐H3: expression analysis of 2IgB7‐H3 on dendritic cells and tumor cellsTissue Antigens, 2005
- Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple MyelomaCancer Research, 2005
- Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCsTissue Antigens, 2004
- Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40Nature Reviews Immunology, 2004
- Prospects for CD40-directed experimental therapy of human cancerCancer Gene Therapy, 2002
- Identification of Rat OX40 Ligand by Molecular CloningBiochemical and Biophysical Research Communications, 1998
- OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligandEuropean Journal of Immunology, 1996
- Gene structure and chromosomal localization of the mouse homologue of rat OX40 proteinEuropean Journal of Immunology, 1995
- The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigenEuropean Journal of Immunology, 1994